Resolution Therapeutics
PrivateLast Round
Series B
Oct 3, 2024
Total Funding Raised
$132.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Resolution Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series B round in October 2024.
Resolution Therapeutics is a biotechnology company developing regenerative macrophage cell therapies to treat inflammatory and fibrotic diseases, with an initial focus on end-stage liver disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Resolution Therapeutics Comparables
Compare Resolution Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Carisma Therapeutics | 77% | |
| KanonCure Inc. | 73% | |
| HepaTx Corporation | 70% |
For institutional investors. Book with your work email.
Resolution Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 3, 2024 | ||||
| Series A Extension | Apr 5, 2022 | ||||
| Series A | Dec 2, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Resolution Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Syncona | Series B, Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 55% MoM, reaching 2.6K.
- Oct 9, 2025
Will present at The Liver Meeting 2025 by AASLD.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 6, 2026
Resolution Tx will present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026 in Colorado on Nov 8th '26.
- is_developingOct 6, 2026
As its initial focus, Resolution Tx is developing RTX001, its lead product, with preclinical data showing anti-fibrotic and anti-inflammatory advantages over non-engineered macrophages.
- is_developingSep 1, 2026
Resolution Tx is developing Regenerative Macrophage Therapy as a potential alternative to liver transplantation that could improve quality and length of life for patients with end-stage liver disease, with RTX001 under investigation in the EMERALD trial at Nottingham University Hospitals in United Kingdom on Aug 25th '26.
- is_developingSep 1, 2026
Resolution Tx is developing RMTs in additional inflammatory and fibrotic indications, including lung fibrosis, and these programs are in preclinical evaluation.
- partners_withSep 1, 2026
Resolution Tx partners with Blood Centers of America to support broad patient access to experimental Regenerative Macrophage Therapy in the United States, with the partnership supporting Resolution Tx's pivotal RTX001 clinical program in 2027 and future commercial preparedness while Blood Centers of America serves as a preferred provider of cell collection and processing services for pivotal study sites.
For institutional investors. Book with your work email.
Resolution Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Resolution Therapeutics's valuation, stock price, and market status.
Is Resolution Therapeutics a public or private company?
Resolution Therapeutics is a private company.
What is the current stock price of Resolution Therapeutics?
Resolution Therapeutics is a private company, so its shares have no public market price. Caplight tracks Resolution Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Resolution Therapeutics worth (valuation)?
Valuation information for Resolution Therapeutics is not publicly available.
Can I buy Resolution Therapeutics stock?
Resolution Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Resolution Therapeutics's last funding round?
Resolution Therapeutics's most recent funding round was Series B on October 3, 2024.
Who are the main investors in Resolution Therapeutics?
Key investors in Resolution Therapeutics include Syncona.
Will Resolution Therapeutics IPO soon?
No public IPO plans have been announced for Resolution Therapeutics.
How can I track Resolution Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Resolution Therapeutics's shares on secondary markets.